Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kumatakenin is a methoxylated flavonoid, specifically the 3,7-dimethyl ether of kaempferol, isolated from plants such as *Varthemia iphionoides* and *Alpinia kumatake*. It is primarily researched as a bioactive lead compound for its antineoplastic and anti-inflammatory properties. In metastatic prostate cancer models, kumatakenin has demonstrated cytotoxic effects by inducing apoptosis and causing mitochondrial membrane potential depolarization. Additionally, it has been shown to inhibit the production of inflammatory cytokines and mediators like nitric oxide (NO) and prostaglandin E2 (PGE2) in stimulated macrophages, suggesting potential applications in inflammatory disorders. Its drug-like ADMET profile further supports its potential as a scaffold for novel therapeutic development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kumatakenin.